Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

The latest health news covers the European Medicines Agency supporting Novo Nordisk’s drug for heart failure in obese ...

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

We’re firmly in the “buyer beware” era of obesity drugs. And unfortunately, it seems like we’re going to be stuck here for a ...

Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...

Discounts of as much as half on the $1,000-plus-a-month injectables are meant to induce insurers to offer coverage to workers ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

After losing market share in recent years, Nike faces near-term challenges such as the sales momentum among competitors. The Federal Trade Commission sued the drug middlemen that health plans use to ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...